17 results on '"Mauleón Fernández, C."'
Search Results
2. Supervivencia de la ciclosporina en el tratamiento de la dermatitis atópica moderada-grave: Registro Español de Dermatitis Atópica (BIOBADATOP)
- Author
-
Couselo-Rodríguez, C., Batalla, A., Carrascosa, J.M., Chicharro, P., González-Quesada, A., de la Cueva, P., Giménez-Arnau, A.M., Gilaberte, Y., Rodríguez-Serna, M., Montero-Vilchez, T., Ruiz-Villaverde, R., Elosua-González, M., Silvestre-Salvador, J.F., Munera-Campos, M., Sánchez-Pérez, J., Carretero, G., Mauleón-Fernández, C., Curto-Barredo, L., Ballano-Ruiz, A., Botella-Estrada, R., Arias-Santiago, S., Navarro-Triviño, F.J., Roustan-Gullón, G., Betlloch, I., del Alcázar, E., Abalde-Pintos, M.T., Suárez-Perez, J., García-Doval, I., Descalzo, M.Á., and Flórez, Á.
- Published
- 2024
- Full Text
- View/download PDF
3. BIOBADATOP: Registro Español de Dermatitis Atópica. Descripción y primeros resultados
- Author
-
Munera-Campos, M., primary, Chicharro, P., additional, Gonzalez Quesada, A., additional, Florez Menendez, A., additional, de la Cueva Dovao, P., additional, Gimenez Arnau, AM., additional, Gilaberte Calzada, Y., additional, Rodríguez Serna, M., additional, Montero, T., additional, Silvestre Salvador, JF., additional, Elosua González, M., additional, del Alcazar, E., additional, Santamaría, C., additional, Sánchez-Pérez, J., additional, Carretero Hernández, G., additional, Batalla Cebey, A., additional, Jin Suh Oh, H., additional, Mauleón Fernández, C., additional, Curto Barredo, L., additional, Bertolín, M., additional, Navarro Bielsa, A., additional, Ballano Ruiz, A., additional, Botella Estrada, R., additional, Arias Santiago, S., additional, Betlloch, I., additional, Roustan Gullón, G., additional, Rosell Díaz, A., additional, Descalzo, MÁ., additional, García-Doval, I., additional, and Carrascosa, JM., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Incidence of Thromboembolic Events in Cancer Hospitalized Patients With COVID-19
- Author
-
Rogado, Jacobo, primary, Obispo, Berta, additional, Muñoz-Rivas, Nuria, additional, Lara, Miguel Angel, additional, Mestre-Gómez, B., additional, Lorente-Ramos, R.M., additional, Rogado, J., additional, Franco-Moreno, A., additional, Obispo, B., additional, Salazar-Chiriboga, D., additional, Saez-Vaquero, T., additional, Torres-Macho, J., additional, Abad-Motos, A., additional, Cortina-Camarero, C., additional, Such-Diaz, A., additional, Ruiz-Velasco, E., additional, Muñoz-Rivas, N., additional, Sierra-Hidalgo, F., additional, Moya-Mateo, E., additional, de Carranza-López, M., additional, Herrera-Morueco, M.A., additional, Akasbi-Montalvo, M., additional, Pardo-Guimerá, V., additional, Medrano-Izquierdo, P., additional, Mariscal-Gómez, E., additional, Marín-Mori, K., additional, Figueras-González, C., additional, López-Lallave, S., additional, Díaz-Díaz, D., additional, Mauleón-Fernández, C., additional, Martín-Navarro, J., additional, Torres-Rubio, P., additional, Matesanz, C., additional, Moro-Alvarez, M.J., additional, Bustamante-Fermosel, A., additional, and Hernández-Rivas, J.A., additional
- Published
- 2021
- Full Text
- View/download PDF
5. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis
- Author
-
Mestre-Gómez, B., Lorente-Ramos, R. M., Rogado, J., Franco-Moreno, A., Obispo, B., Salazar-Chiriboga, D., Saez-Vaquero, T., Torres-Macho, J., Abad-Motos, A., Cortina-Camarero, C., Such-Diaz, A., Ruiz-Velasco, E., Churruca-Sarasqueta, J., Muñoz-Rivas, N., Sierra-Hidalgo, F., Moya-Mateo, E., de Carranza-López, M., Herrera-Moroueco, M. A., Akasbi-Montalvo, M., Pardo-Guimerá, V., Medrano-Izquierdo, P., Mariscal-Gómez, E., Marín-Mori, K., Figueras-González, C., López-Lallave, S., Díaz-Díaz, D., Mauleón-Fernández, C., Martín-Navarro, J., Torres-Rubio, P., Matesanz, C., Moro-Alvarez, M. J., Bustamante-Fermosel, A., and Hernández-Rivas, J. S. A.
- Subjects
Male ,medicine.medical_specialty ,Computed Tomography Angiography ,medicine.drug_class ,Low molecular weight heparin ,030204 cardiovascular system & hematology ,Thrombophilia ,Chemoprevention ,Article ,Fibrin Fibrinogen Degradation Products ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Pulmonary angiography ,Electronic Health Records ,Humans ,Medicine ,Cumulative incidence ,030212 general & internal medicine ,Lung ,Computed tomography angiography ,Antithrombotic therapy ,medicine.diagnostic_test ,SARS-CoV-2 ,business.industry ,Incidence ,Incidence (epidemiology) ,Pulmonary embolism ,COVID-19 ,Anticoagulants ,Hematology ,Middle Aged ,medicine.disease ,COVID-19 Drug Treatment ,Computed tomography pulmonary angiography ,Causality ,Hospitalization ,Spain ,Hypercoagulable state ,Female ,business ,Cardiology and Cardiovascular Medicine ,Dyslipidemia - Abstract
Recent studies suggest that thrombotic complications are a common phenomenon in the novel SARS-CoV-2 infection. The main objective of our study is to assess cumulative incidence of pulmonary embolism (PE) in non critically ill COVID-19 patients and to identify its predicting factors associated to the diagnosis of pulmonary embolism. We retrospectevely reviewed 452 electronic medical records of patients admitted to Internal Medicine Department of a secondary hospital in Madrid during Covid 19 pandemic outbreak. We included 91 patients who underwent a multidetector Computed Tomography pulmonary angiography(CTPA) during conventional hospitalization. The cumulative incidence of PE was assessed ant the clinical, analytical and radiological characteristics were compared between patients with and without PE. PE incidence was 6.4% (29/452 patients). Most patients with a confirmed diagnosed with PE recieved low molecular weight heparin (LMWH): 79.3% (23/29). D-dimer peak was significatly elevated in PE vs non PE patients (14,480 vs 7230 mcg/dL, p = 0.03). In multivariate analysis of patients who underwent a CTPA we found that plasma D-dimer peak was an independen predictor of PE with a best cut off point of > 5000 µg/dl (OR 3.77; IC95% (1.18–12.16), p = 0.03). We found ninefold increased risk of PE patients not suffering from dyslipidemia (OR 9.06; IC95% (1.88–43.60). Predictive value of AUC for ROC is 75.5%. We found a high incidence of PE in non critically ill hospitalized COVID 19 patients despite standard thromboprophylaxis. An increase in D-dimer levels is an independent predictor for PE, with a best cut-off point of > 5000 µg/ dl.
- Published
- 2020
- Full Text
- View/download PDF
6. Malignant Blue Nevus: Report of a New Case: P-167
- Author
-
Chavarria-Mur, E., Rivera, T., Mauleón-Fernández, C., Galiano, S., and de la Cueva, P.
- Published
- 2013
7. Nodular scabies mimicking urticaria pigmentosa in an infant
- Author
-
Mauleón-Fernández, C., Sáez-de-Ocariz, M., Rodríguez-Jurado, R., Durán-McKinster, C., Orozco-Covarrubias, L., and Ruiz-Maldonado, R.
- Published
- 2005
8. Fotoprotección en la infancia
- Author
-
Valdivielso Ramos, M., Mauleón Fernández, C., Balbín Carrero, E., de la Cueva Dobao, P., Chavarría Mur, E., and Hernanz Hermosa, J.M.
- Subjects
Fotoprotectores solares ,Photo protection ,Fotoprotección ,Infancia ,Sun protection ointments ,Child - Abstract
Los niños son el grupo poblacional en el que más debe extremarse la fotoprotección. Son muy sensibles a los efectos negativos derivados de una exposición solar excesiva, y no son conscientes de este riesgo. Los niños desarrollan una actividad al aire libre mucho más importante que los adultos, y la exposición a la radiación ultravioleta y las quemaduras durante la infancia son un factor de riesgo fundamental para el desarrollo de cáncer cutáneo en la edad adulta. Es por tanto de vital importancia proteger al niño de los efectos nocivos de la radiación ultravioleta. Las medidas de fotoprotección incluyen las conductas de evitación solar, la protección con ropa, gorros y gafas solares, y el uso de cremas fotoprotectoras. Las campañas de educación solar deben desarrollarse en los hospitales, en los colegios, y en los medios de comunicación, de forma conjunta entre dermatólogos, pediatras, profesores y responsables gubernamentales. Children are the population group who most need photo protection. They are very sensitive to the negative consequences of an excessive sun exposure, and they aren’t aware of the risk. Children have much more open air activity than adults, and the exposure to ultraviolet radiation and sun burns in childhood are a risk factor of the utmost importance in the development of skin cancer in adulthood. It is therefore of vital relevance to protect the child from the deleterious effects of ultraviolet radiation. The photo protection measures include sun avoidance, protection with cloths, caps and solar glasses, and the use of photo protection ointments. Sun education campaigns should be implemented in hospitals, schools and communication media, and with dermatologists, pediatricians, teachers and political referents altogether.
- Published
- 2009
9. Fotoprotección en la infancia
- Author
-
Valdivielso Ramos, M., primary, Mauleón Fernández, C., additional, Balbín Carrero, E., additional, de la Cueva Dobao, P., additional, Chavarría Mur, E., additional, and Hernanz Hermosa, J.M., additional
- Published
- 2009
- Full Text
- View/download PDF
10. [Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings
- Author
-
Munera-Campos, M., Chicharro, P., Gonzalez Quesada, A., Flórez Menéndez, Á., de la Cueva Dobao, P., Gimenez Arnau, A.M., Gilaberte Calzada, Y., Rodríguez Serna, M., Montero-Vilchez, T., Silvestre, J.F., Elosua-González, M., del Alcázar, E., Santamaría, C., Sánchez-Pérez, J., Carretero Hernández, G., Batalla, A., Jin Suh Oh, H., Mauleón Fernández, C., Curto Barredo, L., Bertolín-Colilla, M., Navarro Bielsa, A., Ballano Ruiz, A., Botella Estrada, R., Arias Santiago, S., Betlloch, I., Roustan Gullón, G., Rosell Díaz, A., Descalzo, M.A., García-Doval, I., and Carrascosa, J.M.
- Abstract
[Display omitted]
- Published
- 2023
- Full Text
- View/download PDF
11. Protocolo diagnóstico diferencial de las lesiones hipopigmentadas
- Author
-
Chavarría Mur, E., primary, Mauleón Fernández, C., additional, and Hernanz Hermosa, J.M., additional
- Published
- 2002
- Full Text
- View/download PDF
12. Protocolo diagnóstico de la hipertricosis
- Author
-
Mauleón Fernández, C., primary, Chavarría Mur, E., additional, and Bueno Marco, C., additional
- Published
- 2002
- Full Text
- View/download PDF
13. Nodular fasciitis | Fascitis nodular
- Author
-
Mauleón Fernández, C., Chavarría Mur, E., Ricardo Suárez - Fernandez, Lázaro Ochaita, P., and Lecona Echeverría, M.
14. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).
- Author
-
Couselo-Rodríguez C, Batalla A, Carrascosa JM, Chicharro P, González-Quesada A, de la Cueva P, Giménez-Arnau AM, Gilaberte Y, Rodríguez-Serna M, Montero-Vilchez T, Ruiz-Villaverde R, Elosua-González M, Silvestre-Salvador JF, Munera-Campos M, Sánchez-Pérez J, Carretero G, Mauleón-Fernández C, Curto-Barredo L, Ballano-Ruiz A, Botella-Estrada R, Arias-Santiago S, Navarro-Triviño FJ, Roustan-Gullón G, Betlloch I, Del Alcázar E, Abalde-Pintos MT, Suárez-Perez J, García-Doval I, Descalzo MÁ, and Flórez Á
- Subjects
- Humans, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use, Prospective Studies, Registries, Treatment Outcome, Dermatitis, Atopic drug therapy, Psoriasis drug therapy
- Abstract
Background: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases., Material and Method: Multicenter, observational, prospective cohort study using data from the Spanish Atopic Dermatitis Registry (BIOBADATOP). Data from the Spanish Registry of Systemic Treatments in Psoriasis (BIOBADADERM) were used to create a comparison cohort., Results: We analyzed data for 130 patients with AD treated with cyclosporine (median drug survival, 1 year). Median cyclosporine survival in the psoriasis comparison group (150 patients) was 0.37 years. Drug survival was significantly longer in AD than in psoriasis (P<.001)., Conclusion: Drug survival of cyclosporine in the BIOBADATOP registry is similar to that described in other series of patients with AD and longer than that observed in the BIOBADADERM psoriasis registry., (Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings.
- Author
-
Munera-Campos M, Chicharro P, Gonzalez Quesada A, Flórez Menéndez Á, de la Cueva Dobao P, Gimenez Arnau AM, Gilaberte Calzada Y, Rodríguez Serna M, Montero-Vilchez T, Silvestre JF, Elosua-González M, Del Alcázar E, Santamaría C, Sánchez-Pérez J, Carretero Hernández G, Batalla A, Jin Suh Oh H, Mauleón Fernández C, Curto Barredo L, Bertolín-Colilla M, Navarro Bielsa A, Ballano Ruiz A, Botella Estrada R, Arias Santiago S, Betlloch I, Roustan Gullón G, Rosell Díaz A, Descalzo MA, García-Doval I, and Carrascosa JM
- Subjects
- Humans, Prospective Studies, Cyclosporine therapeutic use, Administration, Cutaneous, Registries, Treatment Outcome, Severity of Illness Index, Dermatitis, Atopic drug therapy, Dermatitis, Atopic epidemiology
- Abstract
Background: In recent years, remarkable improvements in our understanding of atopic dermatitis (AD) have revolutionized treatment perspectives, but access to reliable data from clinical practice is essential., Materials and Method: The Spanish Atopic Dermatitis Registry, BIOBADATOP, is a prospective, multicenter database that collects information on patients of all ages with AD requiring systemic therapy with conventional or novel drugs. We analyzed the registry to describe patient characteristics, diagnoses, treatments, and adverse events (AEs)., Results: We studied data entries for 258 patients who had received 347 systemic treatments for AD. Treatment was discontinued in 29.4% of cases, mostly due to a lack of effectiveness (in 10.7% of cases). A total of 132 AEs were described during follow-up. Eighty-six AEs (65%) were linked to a systemic treatment, most commonly dupilumab (39AEs) and cyclosporine (38AEs). The most common AEs were conjunctivitis (11patients), headache (6), hypertrichosis (5), and nausea (4). There was 1severe AE (acute mastoiditis) associated with cyclosporine., Conclusions: Initial findings on AEs from the Spanish BIOBADATOP registry are limited by short follow-up times precluding comparisons or calculation of crude and adjusted incidence rates. At the time of our analysis, no severe AEs had been reported for novel systemic therapies. BIOBADATOP will help answer questions on the effectiveness and safety of conventional and novel systemic therapies in AD., (Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
16. Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study.
- Author
-
Muñoz-Rivas N, Abad-Motos A, Mestre-Gómez B, Sierra-Hidalgo F, Cortina-Camarero C, Lorente-Ramos RM, Torres-Rubio P, Arranz-García P, Franco-Moreno AI, Gómez-Mariscal E, Mauleón-Fernández C, Alonso-García S, Rogado J, Saez-Vaquero T, Such-Diaz A, Ryan P, Moya-Mateo E, Martín-Navarro JA, Hernández-Rivas JA, Torres-Macho J, and Churruca J
- Subjects
- Aged, Aged, 80 and over, Disseminated Intravascular Coagulation diagnosis, Disseminated Intravascular Coagulation drug therapy, Disseminated Intravascular Coagulation etiology, Female, Humans, Male, Middle Aged, Retrospective Studies, SARS-CoV-2 isolation & purification, Thrombophilia diagnosis, Thrombophilia drug therapy, Thrombophilia etiology, Thrombosis diagnosis, Venous Thromboembolism diagnosis, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Anticoagulants therapeutic use, COVID-19 complications, Heparin, Low-Molecular-Weight therapeutic use, Thrombosis drug therapy, Thrombosis etiology
- Abstract
Background: Incidence of thrombotic events associated to Coronavirus disease-2019 (COVID-19) is difficult to assess and reported rates differ significantly. Optimal thromboprophylaxis is unclear., Objectives: We aimed to analyze the characteristics of patients with a confirmed thrombotic complication including inflammatory and hemostatic parameters, compare patients affected by arterial vs venous events and examine differences between survivors and non-survivors. We reviewed compliance with thromboprophylaxis and explored how the implementation of a severity-adjusted protocol could have influenced outcome., Methods: Single-cohort retrospective study of COVID-19 patients admitted, from March 3 to May 3 2020, to the Infanta Leonor University Hospital in Madrid, epicenter of the Spanish outbreak., Results: Among 1127 patients, 80 thrombotic events were diagnosed in 69 patients (6.1% of the entire cohort). Forty-three patients (62%) suffered venous thromboembolism, 18 (26%) arterial episodes and 6 (9%) concurrent venous and arterial thrombosis. Most patients (90%) with a confirmed thrombotic complication where under low-molecular-weight heparin treatment. Overt disseminated intravascular coagulation (DIC) was rare. Initial ISTH DIC score and pre-event CRP were significantly higher among non-survivors. In multivariate analysis, arterial localization was an independent predictor of mortality (OR = 18, 95% CI: 2.4-142, p < .05)., Conclusions: Despite quasi-universal thromboprophylaxis, COVID-19 lead to a myriad of arterial and venous thrombotic events. Considering the subgroup of patients with thrombotic episodes, arterial events appeared earlier in the course of disease and conferred very poor prognosis, and an ISTH DIC score ≥ 3 at presentation was identified as a potential predictor of mortality. Severity-adjusted thromboprophylaxis seemed to decrease the number of events and could have influenced mortality. Randomized controlled trials are eagerly awaited., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
17. [Eccema herpeticum].
- Author
-
Mauleón Fernández C, Silvente San Nicasio C, Valdivielso Ramos M, and Chavarría Mur E
- Subjects
- Acyclovir therapeutic use, Adrenal Cortex Hormones adverse effects, Adrenal Cortex Hormones therapeutic use, Adult, Antiviral Agents therapeutic use, Cyclosporine adverse effects, Cyclosporine therapeutic use, Dermatitis, Atopic complications, Dermatitis, Atopic drug therapy, Dermatitis, Atopic immunology, Eczema drug therapy, Eczema immunology, Eczema virology, Herpes Simplex drug therapy, Herpes Simplex immunology, Humans, Immunocompromised Host, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Male, PUVA Therapy adverse effects, Eczema etiology, Herpes Simplex diagnosis, Simplexvirus physiology, Virus Activation
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.